start friday product avail client
direct distribut list extern platform pleas reach leerink
repres would like receiv
regulatori event fda adcom joint anesthet analges drug product
pleas refer disclosur appendix analyst certif import disclosur price chart
disclosur specif cover compani avail
contact leerink partner editori depart statement valuat risk avail note
follow public contact leerink partner editori depart rx trend deriv im
medic meet american heart associ link preview impella stemi
durabl pipelin underappreci initi op
sotp cash flow discount rate
bottom line initi outperform rate sotp-bas pt
invest thesi four-fold manag final rebas number growth expect
credibl level balanc sheet becom less focu allow investor focu
key driver underli growth base busi underappreci investor
driven three franchis medic aesthet emerg market vraylar pipelin
valu stock given base busi growth assumpt valu base busi
expect stock multipl expans investor increasingli appreci
allergan durabl asset increas share busi today almost
compani year
catalyst watch includ
leerink proprietari research underscor conclus
pt base sotp base busi plu pipelin discount
revenu adj ep fulli dilut
rimegep stori initi op rate pt
cash flow discount rate
bottom line initi op rate sotp-bas pt invest
thesi four-fold think migrain space signific market brand
acut segment underappreci biohaven monet strong rimegep clinic profil
like commerci partner potenti go alon strategi glutam
platform/pipelin get minim attent due signific investor focu cgrp platform
compani multipl shot goal area could sourc upsid recent in-
licens product multipl system atrophi nice sale opportun
given recent deal complet product convers yet
manag strong scientif background neurosci expect use busi
develop continu build pipelin
catalyst watch includ
leerink proprietari research underscor conclus
pt base sotp analysi forecast cash flow discount rate
link industri report initi neurosci sector full coverag univers
like new epilepsi drug initi gwph op rate
sotp cash flow discount rate
bottom line initi gwph op rate sotp-bas pt
invest thesi four-fold think lead product epidiolex cbd dravet syndrom
lennox gastaut syndrom approv us blockbust drug sale
base posit feedback medacorp physician survey kol interview
second product sativex nabiximol multipl sclerosi spastic receiv minim attent
believ could grab global sale sativex current approv market
europ row expect approv us epilepsi high oper
margin busi model sale forecast drive strong bottom-lin profit
compani deep cannabinoid scienc platform proprietari know-how area enabl
develop addit product sustain growth
catalyst watch includ
leerink proprietari research underscor conclus
pt base sotp analysi forecast cash flow discount
pleas use follow link industri report initi neurosci sector full
model decemb year-end earn per basic
like fintepla stori initi op rate pt
cash flow discount rate
bottom line initi coverag outperform rate sotp-bas
pt invest thesi four-fold like epilepsi market novel drug
physician enthusiasm new agent base high unmet need frequent switch use multi-
drug regimen rel low payer pushback believ fintepla strong clinic profil
drive sale base compani price comment survey physician
excit use product on-label orphan epilepsi patient well off-label
refract popul epilepsi high oper margin busi model sale forecast
drive strong bottom-lin profit believ manag cash experi
execut smart busi develop bd decis build pipelin time
catalyst watch includ
leerink proprietari research underscor conclus
pt base sotp analysi forecast cash flow discount
revenu
recap upgrad op valuat phase data
 methodolog blend discount sale multipl analysi dcf w/ discount
bottom line report financi result provid pipelin updat larg
in-lin expect next key catalyst stock initi
phase dose-escal data potenti phase
updat upgrad rate op mp previous valuat
stock trade histor low enterpris valu continu view
led experienc high qualiti manag team two program advanc phase clinic
studi updat program expect within next month howev stori
continu face obstacl move forward especi relat competit landscap
abil overcom roch past disappoint believ investor sentiment
follow brief clinic hold place subsequ lift follow amend
trial protocol depress stock current level view upcom data readout key
valid clinic program well safeti overal platform upgrad op
pt remain
next key catalyst first clinic data expect
select phase ii dose expect
preclin present tripl meet
end cash equival expect fund oper
revenu present mm ep quarterli figur may sum annual total due
chang share outstand
bottom line fl ga recount recent win first democrat senat seat
az sinc weigh coverag final result like drag come days/
week regardless pend race purpl divid congress hous democrat
major senat republican major bode well whole pend
outcom republican could hold slim seat major senat pend fl ms
win could determin eas potenti republican judiciari appoint state governor
race fl ga look pois remain republican desanti kemp lower probabl
scenario turn democrat gillum abram win see republican state legislatur
still like drive gridlock state level less probabl medicaid expans liber
agenda come fruition clariti offer thursday allow coverag univers trade
back continu run fundament see last trickl elect news flow nois
opportun buy weak like mco unh-op antm-op ci-op hum-op wcg-
op moh-op cnc-op within facil op op op md op
op op payor servic strong buy call scenario given bipartisan support
technology-en servic drive cost qualiti outcom
fl senat governor race head contenti recount republican hold slim lead
race
ga governor race undecid republican hold slim lead
ms senat race head runoff candid gain vote
pend senat race could determin eas republican judici appoint tx lawsuit
question constitution like head conserv lean suprem court
purpl congress preserv pre-exist condit provis make legisl repeal
obamacar imposs bode well low-double-digit exposur exchang
midterm mix medicaid stock op op fl ga expans difficult even
democrat governor win
medicaid expans ballot initi id ne ut pass democrat governor ks wi
potenti expand coverag mt ak expans remain risk
continu bullish medicar advantag focus payor op flagship
given control polici key lever drive privat
hc servic perspect likewis bullish diversifi mco captiv pbm
specialti pharmaci unh/optum antm/ingenio rx ci op esrx mp believ
best posit bend cost curv take share
wcg op well-balanc teflon stock diversifi medicaid part polici downsid
hix
facil benefit medicaid expans continu tax reform tailwind bipartisan support
payor servic continu outperform
pharma elect trade
catalyst rich data clinic program ind
outperform market cap price price target methodolog dcf
discount rate termin growth rate
bottom line report earn market close today broaden
pipelin leadership new presid ceo dr aoif brennan former interim ceo
follow encourag interim data link updat
provid increment insight program link link emerg potenti promis
immuno-oncolog i/o program link continu view broad potenti sybx
platform compel compani develop program in-hous partnership ie
mp inflammatori bowel diseas look forward catalyst-rich valid
technolog program indic ind submiss could mark
begin immuno-oncolog franchis reiter outperform pt
top-line data phenylketonuria pku patient present medic
top-lin data liver cirrhosi hepat encephalopathy/h
delay data urea cycl disord
potenti util sybx platform broaden rapidli addit third program
immuno-oncolog io ind submiss
revenu mm ep present valu includ estim
chang outlook wait clinic data pt
dcf wacc termin growth rate
bottom line last thursday releas financi result
yet provid insight safeti efficaci mrna messeng rna platform
human still believ tbio mrna-bas platform remain promis provid
abil expand multipl rare diseas state valid recent collabor
sanofi remain track begin multipl ascend dose portion phase
cftr clinic trial end expect expand mrna platform ornithin
transcarbamylas over-the-counter defici rare diseas
continu enrol dose patient lead mrna drug
updat model recent quarter result price target increas
revenu mm non-gaap ep
potenti delay vyleesi underscor risk pipelin
bottom line morn manag indic fda request addit
phase studi order help better character impact frequent dose inform
vyleesi label investor expect asset low believ news like
put addit pressur stock manag believ data could delay potenti
approv month origin march pdufa date low convict
asset due low market penetr sq method administr rather risk approv
time delay certainli bode well stock especi next month multipl
im intramuscular gener makena could start come around year-end intrarosa sale
continu small reiter mp
advanc ahead schedul multipl poc event around corner
wacc lt growth rate
bottom line morn aptinyx announc financi result updat investor
on-going progress phase ii pain diabet peripher neuropathi dpn
fibromyalgia fm program compani appear progress ahead
expect three program clinic develop importantli compani disclos
exploratori interim analysi phase ii fibromyalgia studi decemb aptinyx
also tighten guidanc top-line phase ii data dpn earli vs first half previous
updat confirm effect compani enrol effort implic unmet
need indic dont assum increas odd success acceler time
although probabl encourag discourag event updat also establish sever
near term catalyst larg part determin futur valu
associ least aptinyx platform
revenu mm ep
continu efficaci safeti updat aasld enhanc trial
bottom line seladelpar updat primari biliari cholangitis/ pbc american associ
studi liver diseas aasld meet support optim could promis treatment
option second-lin set stock seem pressur due appar concern
wane efficaci evidenc bilirubin trend higher week seen mg arm
titrat arm meanwhil alkalin phosphatas ap look durabl contain may
import biomark addit disclosur pt discontinu although due
grade gastroesophag reflux total pt discontinu to-dat pt receiv least
dose seladelpar discontinu previous think neg stock reaction
overreact importantli pivot enhanc trial way drug could come
market sooner estim may even challeng lead held intercept mp
recap data xlrp chm remain on-track
analysi discount rate termin growth rate
bottom line remain on-track potenti becom first gene therapi
choroideremia chm focu broaden compani second asset nsr-rpgr x-
link retin pigmentosa/xlrp catalyst along financi result announc
management also provid addit clariti upcom xiriu expans studi
could help defin futur regulatori path rare ophthalm indic reiter op
pt nite
financi provid part ipo semi-annu report adopt quarterli
result onward
recap pipelin track ind file pku
dcf analysi revenu multipl dr tgr
bottom line report financi result provid pipelin updat consist
expect differenti preclin stage cell therapi compani develop red cell
therapi consist genet engin red blood cell express therapeut protein
within surfac cell bloodi approach initi op pt
number potenti advantag cell therapi platform base red blood cell includ
off-the-shelf approach potenti broad therapeut applic rare diseas oncolog
autoimmun diseas howev still number develop risk point given
earli stage develop first ind file expect acknowledg valuat
method signific shortcom earli stage clear us swing
fenc type play approach uniqu differenti could potenti transform
cell therapi field success addit view well posit execut
strategi experienc manag team strong financi posit overal posit
long-term view stock reiter op
driven lower spend chang furoscix resubmiss
outperform market cap price price target methodolog dcf cash
flow use discount rate
bottom line morn manag report ep vs lp estim
consensu differ due lower spend sg
vs estim previous highlight takeaway type meet
manag today reiter expect complet human factor dose deliveri valid
studi support resubmiss furoscix continu see long-term valu given
furoscix valu proposit improv outcom heart failur patient lower hospit cost
drive sale reiter op
recap addit patient dose total random prelim data
discount rate termin growth rate
bottom line cur potenti duchenn muscular dystrophi dmd horizon
gene therapi continu advanc clinic aim deliv lead drug
candid part sldb earn compani provid encourag updat
speak manag believ news posit previous publish
micro-dystrophin deep dive link news good news addit patient dose first
patient dose result trial place clinic hold lift link total patient
random ignit studi patient activ treatment group vs patient
delay treatment group compani provid preliminari microdystrophin
express biopsi data ahead interim analysi compani previous guid
look forward updat could provid sign efficaci reiter outperform pt
pivot trial seem quarter later outlook intact pt
bottom line earlier today report financi result
compani alreadi provid addit result phase trial respiratori
tract infect rti link earlier quarter press releas compani suggest
end-of-phas meet fda rather chang
time probabl materi delay catalyst initi pivot trial
rti prevent month least believ posit result prior
studi support transit phase prevent rti still plan initi
program first half addit data analysi trial suggest treatment
also meaning reduct urinari tract infect uti compar placebo
compani continu refin clinic strategi uti expect
sort announc studi around year end
neurosci initi neurosci posit
downgrad mp scale competit carve-out model pose
 methodolog ep
medacorp puls call physician view stemi earli still feasibl
ev/sal multipl estim
agreement lannett allow amneal fulli realiz levo opportun
go privat outcom given market headwind
investor brief provid i/o clinic regulatori updat
discuss around approv prospect gener advair posit earn
manag indic complet respons letter june includ minor
label chemistri manufactur control relat question
submit respons mid-juli standard three month goal date
although hope sinc product prioriti design approv could come
manag emphas addit data requir part respons
remain readi launch upon approv
compani develop varlitinib indic high preval asia includ
biliari tract cancer gastric cancer
asln expect multipl data readout includ
interim readout phase i/ii studi varlitinib gemcitabin cisplatin line
top-lin data global phase ii/iii studi varlitinib folfox co-
interim data ph ii studi dhodh inhibitor acut myeloid leukemia
regulatori settlement behavior health feder state agenc appear like
posit catalyst
negoti remain on-going manag optimist settlement reach
investig state feder regul year
settlement reserv increas pre-tax
given superl clinic data present date expect fda approv
nov link note
larotrectinib loxo lead agent potent specif pan-trk tropomyosin receptor
kinas inhibitor combat basket tumor includ lung breast colon
trk biomark individu estim us
larotrectinib next-gen trk inhibitor partner bayer hold
ex-u commerci right pay loxo tier double-digit royalti ex-u sale
loxo bayer co-develop us cost profit split loxo
receiv up-front payment potenti receiv mileston payment
us ou larotrectinib
project combin larotrectinib peak probability-of-success
adjust sale us europ larotrectinib eu
submit august
dec epo patent challeng relat rubraca ovarian prostat
dec european patent offic epo hear oral argument render
opinion patent challeng camsyl salt patent provid ip protect
eu drug rubraca
challeng file divis sandoz anonym parti contend
epo patent recent grant clovi novel -- argument preliminari
opinion agre cite prior art exist applic file
medacorp specialist review preliminari opinion render april felt
opposit strong argument could result narrow patent claim
claim narrow eu could make invent step difficult
uphold unexpect product attribut may compar broadli potenti
open door prior art consid
view eu patent challeng relev impact potenti
takeout option potenti read-through us exclus
composit matter patent expir without addit patent support drug
intellectu properti ip runway relev us patent howev like
hotli debat even dec goe poorli
sourc leerink research compani inform factset price prior day
fda adcom joint anesthet analges drug product drug safeti
pdufa roxicodon abuse-deterr formul immediate-releas single-
fda adcom scienc advisori board circulatori system devic
fda adcom joint anesthet analges drug product drug safeti
north carolina dhh award rfp transit medicaid program manag
may texa hhsc award rfp star plu medicaid manag care program
american heart associ link preview impella stemi
societi neuro-oncolog
american colleg allergi asthma immunolog
intern societi pediatr oncolog
radiolog societi north america
life scienc biolog engin confer
societi urolog oncolog
intern feder adipos therapeut scienc
asian pacif societi respirolog
american societi hematolog present pst
sadal studi abstract session
abstract paraxysm nocturn hemoglobinuria
american societi health-system pharmacist
intern symposium als/mnd
american societi cell biolog
american colleg neuropsychopharmacolog
manag end sell season
univers coverag
calendar event
model model aptx nite scph
recent updat pleas contact leerink repres wish
review
biopharma preview gener pain women health anti-infect
 biotech earn unlik offer much excit best
hcit distribut preview price pressur continu gener
medic suppli devic individu co preview cardio large-cap diversifi
medic suppli devic individu co preview ortho supplies/cap equipment/
payor servic posit catalyst
arql -- flash increment new data disclos abstract present
impress beta-th
-- flash abstract show strong symptom relief advanc sm import
imdz -- flash minor updat abstract market perform
-- flash abstract encourag investor focu remain forward-i
-- flash multipl present full sadal data confer outperform
-- flash data abstract still earli present
-- flash abstract highlight earli efficaci present
 disappoint ctad fade prospect ban bace market
-- flash data thin unconvinc benefit limit carrier
 ctad disclosur unlik bolster amyloid outlook market perform
